₹2159.05 6.1 0.3%
Last Trade - 13/04/21
| Market Cap | £2.66bn |
| Enterprise Value | £2.59bn |
| Revenue | £522.1m |
| Position in Universe | 148th / 3106 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Mar | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 31,418 | 29,065 | 32,106 | 32,852 | 37,750 | 46,499 | 55,285 | 60,825 | +8.2% | ||
| -46.6 | -63.2 | +108.4 | +21.8 | +85.7 | +39.8 | +89.8 | -2.93 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Ipca Laboratories Limited is engaged in pharmaceuticals business. The Company is a manufacturer and supplier of over 10 active pharmaceutical ingredients (APIs). It offers APIs, such as atenolol, hydroxychloroquine sulfate, morantel citrate, pyrantel pamoate and zaltoprofen. It offers brands, such as Zerodol, Lariago, HCQS Perinorm, Rapither, Tenoric, Lumerax, Etova, Malirid and Folitrax. Its 3c division focuses on cardiovascular and anti-diabetic markets. Its 3d division is focused on cardio-diabetic market. The Company's activa division serves the rheumatology market. Its altus division caters to the needs of intensivists, both surgical and non-surgical. Its Bionova division's focus area is dermatology. Its dynamix division focuses on cardiovascular, gastro-intestinal, anti-bacterial, pain management and respiratory sectors. It hycare division caters to the needs of cardiologists and diabetologists. Its divisions also include innova, intima, pain management, pharma and uro sciences.
| Last Annual | March 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | October 19, 1949 |
| Public Since | February 23, 1994 |
| No. of Shareholders: | 85,181 |
| No. of Employees: | 14,066 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | |
| Exchange | National Stock Exchange of India |
| Shares in Issue | 126,852,109 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | 142 AB Kandivli Industrial Estate,Kandivli (West), MUMBAI, 400067, India |
| Web | http://www.ipcalabs.com |
| Phone | +91 22 66474747 |
| Contact | () |
| Auditors | G.M. Kapadia & Co. |
As of 13/04/21, shares in IPCA Laboratories are trading at ₹2159.05, giving the company a market capitalisation of £2.66bn. This share price information is delayed by 15 minutes.
Shares in IPCA Laboratories are currently trading at ₹2159.05 and the price has moved by 39.09% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the IPCA Laboratories price has moved by -12.53% over the past year.
Of the analysts with advisory recommendations for IPCA Laboratories, there are there are currently 7 "buy" , 5 "hold" and 1 "sell" recommendations. The overall consensus recommendation for IPCA Laboratories is Hold. You can view the full broker recommendation list by unlocking its StockReport.
IPCA Laboratories is scheduled to issue upcoming financial results on the following dates:
The IPCA Laboratories dividend yield is 0.37% based on the trailing twelve month period.
Last year, IPCA Laboratories paid a total dividend of 8, and it currently has a trailing dividend yield of 0.37%. Looking ahead, IPCA Laboratories has not announced an ex-dividend date yet.
IPCA Laboratories has yet to annouce their ex-dividend date. The historic dividend yield on IPCA Laboratories shares is currently 0.37%.
To buy shares in IPCA Laboratories you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in IPCA Laboratories are currently trading at ₹2159.05, giving the company a market capitalisation of £2.66bn.
Here are the trading details for IPCA Laboratories:
Based on an overall assessment of its quality, value and momentum, IPCA Laboratories is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in IPCA Laboratories are currently priced at ₹2159.05. At that level they are trading at 8.12% discount to the analyst consensus target price of 0.00.
Analysts covering IPCA Laboratories currently have a consensus Earnings Per Share (EPS) forecast of 93.634 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like IPCA Laboratories. Over the past six months, the relative strength of its shares against the market has been -15.95%. At the current price of ₹2159.05, shares in IPCA Laboratories are trading at 6.84% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The IPCA Laboratories PE ratio based on its reported earnings over the past 12 months is 25.64. The shares are currently trading at ₹2159.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
IPCA Laboratories's management team is headed by:
Here are the top five shareholders of IPCA Laboratories based on the size of their shareholding:
